Literature DB >> 33817893

Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma.

Tavarekere N Nagaraja1, Rasha Elmghirbi2,3, Stephen L Brown4, Julian A Rey5, Lonni Schultz1, Abir Mukherjee6, Glauber Cabral2, Swayamprava Panda2, Ian Y Lee1, Malisa Sarntinoranont5, Kelly A Keenan1, Robert A Knight2,3, James R Ewing2,3,7.   

Abstract

The effect of a human vascular endothelial growth factor antibody on the vasculature of human tumor grown in rat brain was studied. Using dynamic contrast-enhanced magnetic resonance imaging, the effects of intravenous bevacizumab (Avastin; 10 mg/kg) were examined before and at postadministration times of 1, 2, 4, 8, 12 and 24 h (N = 26; 4-5 per time point) in a rat model of orthotopic, U251 glioblastoma (GBM). The commonly estimated vascular parameters for an MR contrast agent were: (i) plasma distribution volume (vp ), (ii) forward volumetric transfer constant (Ktrans ) and (iii) reverse transfer constant (kep ). In addition, extracellular distribution volume (VD ) was estimated in the tumor (VD-tumor ), tumor edge (VD-edge ) and the mostly normal tumor periphery (VD-peri ), along with tumor blood flow (TBF), peri-tumoral hydraulic conductivity (K) and interstitial flow (Flux) and tumor interstitial fluid pressure (TIFP). Studied as % changes from baseline, the 2-h post-treatment time point began showing significant decreases in vp , VD-tumor, VD-edge and VD-peri , as well as K, with these changes persisting at 4 and 8 h in vp , K, VD-tumor, -edge and -peri (t-tests; p < 0.05-0.01). Decreases in Ktrans were observed at the 2- and 4-h time points (p < 0.05), while interstitial volume fraction (ve ; = Ktrans /kep ) showed a significant decrease only at the 2-h time point (p < 0.05). Sustained decreases in Flux were observed from 2 to 24 h (p < 0.01) while TBF and TIFP showed delayed responses, increases in the former at 12 and 24 h and a decrease in the latter only at 12 h. These imaging biomarkers of tumor vascular kinetics describe the short-term temporal changes in physical spaces and fluid flows in a model of GBM after Avastin administration.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Avastin, DCE-MRI, distribution volume, GBM, Ktrans, Magnevist, peri-tumoral fluid flow, rat, tumor interstitial fluid pressure

Mesh:

Substances:

Year:  2021        PMID: 33817893      PMCID: PMC8978145          DOI: 10.1002/nbm.4516

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  66 in total

1.  Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.

Authors:  Weijun Wang; Walavan Sivakumar; Shering Torres; Niyati Jhaveri; Vijaya Pooja Vaikari; Alex Gong; Adam Howard; Encouse B Golden; Stan G Louie; Axel H Schönthal; Florence M Hofman; Thomas C Chen
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

2.  Intratumor distribution and test-retest comparisons of physiological parameters quantified by dynamic contrast-enhanced MRI in rat U251 glioma.

Authors:  Madhava P Aryal; Tavarekere N Nagaraja; Stephen L Brown; Mei Lu; Hassan Bagher-Ebadian; Guangliang Ding; Swayamprava Panda; Kelly Keenan; Glauber Cabral; Tom Mikkelsen; James R Ewing
Journal:  NMR Biomed       Date:  2014-08-14       Impact factor: 4.044

Review 3.  Efficacy and safety of bevacizumab in glioblastomas.

Authors:  S De Fazio; E Russo; M Ammendola; E Donato Di Paola; G De Sarro
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Toward a noninvasive estimate of interstitial fluid pressure by dynamic contrast-enhanced MRI in a rat model of cerebral tumor.

Authors:  Rasha Elmghirbi; Tavarekere N Nagaraja; Stephen L Brown; Kelly A Keenan; Swayamprava Panda; Glauber Cabral; Hassan Bagher-Ebadian; George W Divine; Ian Y Lee; James R Ewing
Journal:  Magn Reson Med       Date:  2018-03-09       Impact factor: 4.668

5.  Peritumoral tissue compression is predictive of exudate flux in a rat model of cerebral tumor: an MRI study in an embedded tumor.

Authors:  James R Ewing; Tavarekere N Nagaraja; Madhava P Aryal; Kelly A Keenan; Rasha Elmghirbi; Hassan Bagher-Ebadian; Swayamprava Panda; Mei Lu; Tom Mikkelsen; Glauber Cabral; Stephen L Brown
Journal:  NMR Biomed       Date:  2015-10-01       Impact factor: 4.044

6.  A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

Authors:  M J Paldino; A Desjardins; H S Friedman; J J Vredenburgh; D P Barboriak
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

7.  Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening.

Authors:  James R Ewing; Robert A Knight; Tavarekere N Nagaraja; John S Yee; Vijaya Nagesh; Polly A Whitton; Lian Li; Joseph D Fenstermacher
Journal:  Magn Reson Med       Date:  2003-08       Impact factor: 4.668

8.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

Review 9.  Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Authors:  Sohita Dhillon
Journal:  BioDrugs       Date:  2013-08       Impact factor: 5.807

10.  Differential response of patient-derived primary glioblastoma cells to environmental stiffness.

Authors:  Thomas James Grundy; Ellen De Leon; Kaitlyn Rose Griffin; Brett William Stringer; Bryan William Day; Ben Fabry; Justin Cooper-White; Geraldine Margaret O'Neill
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

View more
  3 in total

1.  Adaptation of laser interstitial thermal therapy for tumor ablation under MRI monitoring in a rat orthotopic model of glioblastoma.

Authors:  Tavarekere N Nagaraja; Seamus Bartlett; Katelynn G Farmer; Glauber Cabral; Robert A Knight; O Grahm Valadie; Stephen L Brown; James R Ewing; Ian Y Lee
Journal:  Acta Neurochir (Wien)       Date:  2021-09-23       Impact factor: 2.216

2.  LncRNA MIR4435-2HG functions as a ceRNA against miR-125a-5p and promotes neuroglioma development by upregulating TAZ.

Authors:  Wangzhen Shen; Jiawei Zhang; Yunfeng Pan; Yun Jin
Journal:  J Clin Lab Anal       Date:  2021-10-29       Impact factor: 2.352

3.  A computational model of glioma reveals opposing, stiffness-sensitive effects of leaky vasculature and tumor growth on tissue mechanical stress and porosity.

Authors:  Julian A Rey; James R Ewing; Malisa Sarntinoranont
Journal:  Biomech Model Mechanobiol       Date:  2021-08-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.